Related Experiment Videos
Biological response modifiers in the management of patients with breast cancer
1Biological Response Modifiers Program, National Cancer Institute-Frederick Cancer Research and Development Center, Maryland 21701.
Abstract:
Despite impressive progress in understanding the biology of breast cancer, mechanisms of host defense, and the pathophysiology of the metastatic process, this burgeoning fact bank has made little impact on the management of patients with breast cancer. There are many interesting ideas for improved diagnosis and therapy in various stages of development, but few have actually translated into improved survival of patients with breast cancer. Potentially useful biological agents include cytokines, monoclonal antibodies, immunotoxins, vaccines, and adoptive cellular therapies. Therapies targetting growth factor receptors and the cellular machinery required for metastasis may become useful, especially when used in combination with other cytotoxic agents. Colony-stimulating factors may allow a test of the hypothesis that augmented dose-intensity of cytotoxic chemotherapy will cure more patients. Though we are not yet sure precisely how to use all of these new tools, there can be little doubt that their application will make a significant impact on the management of patients with breast cancer and other malignancies in the next decade.
Insights
Despite advances in breast cancer biology, new therapies like cytokines, antibodies, and vaccines show promise for improving patient survival. Further research is needed to integrate these innovative treatments into clinical practice.
Area of Science:
- Oncology
- Immunology
- Cancer Biology
Background:
- Significant progress in understanding breast cancer biology, host defense, and metastasis has not yet translated into improved patient survival.
- Current breast cancer management faces challenges in translating research findings into clinical benefits.
Purpose of the Study:
- To review emerging biological agents and therapeutic strategies for breast cancer management.
- To explore the potential impact of novel therapies on patient survival and clinical outcomes.
Main Methods:
- Review of current research on biological agents including cytokines, monoclonal antibodies, immunotoxins, vaccines, and adoptive cellular therapies.
- Discussion of targeted therapies for growth factor receptors and metastasis.
- Consideration of colony-stimulating factors for optimizing chemotherapy dose-intensity.
Main Results:
- Several biological agents and targeted therapies are in development for breast cancer treatment.
- Combination therapies and optimized chemotherapy regimens show potential for improved efficacy.
- New tools are emerging that are expected to significantly impact breast cancer management.
Conclusions:
- Novel therapeutic strategies, including biological agents and targeted therapies, hold significant promise for advancing breast cancer treatment.
- The integration of these new tools into clinical practice is anticipated to improve patient survival and outcomes in the next decade.
- Further research is crucial to determine the optimal application of these innovative approaches in managing breast cancer and other malignancies.